Skip to content
Biodatica
Start free

Galmed Pharmaceuticals Ltd

Richmond, Virginia

OncologyPhase IIListed · GLMD

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

NIH U01 · $0.4M · Liver Cirrhosis Network: Clinical Research Centers

10mo agoGrant renewalSep 3, 2025Source filing (opens the source filing in a new tab)

Momentum

60no change

Momentum 60 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    UG3 · $1.2M · non-dilutive

    Sep 15, 2025

    VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · NIDA · award ends Aug 31, 2027 · Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder

    NIH RePORTER · NIH RePORTER 11179692 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jun 1, 2025

    Primary Sclerosing Cholangitis · WITHDRAWN · sponsor: Galmed Pharmaceuticals Ltd · A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

    ClinicalTrials.gov · NCT06095986 (opens the source filing in a new tab)

  3. Grant

    P01 · $574k · non-dilutive

    Aug 8, 2024

    VIRGINIA COMMONWEALTH UNIVERSITY · PI SANYAL, ARUN J · NCI · award ends Jul 31, 2029 · Bile Acid-Mediated Signaling In HCC

    NIH RePORTER · NIH RePORTER 11159519 (opens the source filing in a new tab)

  4. Grant

    R01 · $534k · non-dilutive

    Sep 15, 2022

    VIRGINIA COMMONWEALTH UNIVERSITY · PI SANYAL, ARUN J · NIDDK · award ends Jun 30, 2027 · Predicting outcomes in nonalcoholic steatohepatitis with advanced fibrosis

    NIH RePORTER · NIH RePORTER 11162354 (opens the source filing in a new tab)

  5. Grant

    U01 · $363k · non-dilutive

    Sep 13, 2021

    VIRGINIA COMMONWEALTH UNIVERSITY · PI SANYAL, ARUN J · NIDDK · award ends Jul 31, 2027 · Liver Cirrhosis Network: Clinical Research Centers

    NIH RePORTER · NIH RePORTER 11169754 (opens the source filing in a new tab)

  6. Grant

    U01 · $342k · non-dilutive

    Aug 1, 2018

    VIRGINIA COMMONWEALTH UNIVERSITY · PI ARAB, JUAN PABLO · NIAAA · award ends Jun 30, 2029 · Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) - Virginia Commonwealth University

    NIH RePORTER · NIH RePORTER 11195166 (opens the source filing in a new tab)

  7. Grant

    U01 · $250k · non-dilutive

    May 20, 2002

    VIRGINIA COMMONWEALTH UNIVERSITY · PI SANYAL, ARUN J · NIDDK · award ends Jun 30, 2027 · Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

    NIH RePORTER · NIH RePORTER 11166517 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources